
    
      A randomized double-blind clinical trial, to determine the effect of combined therapy of oral
      prolonged-release metformin/glimepiride in a single dosage form on fasting glucose and HbA1c.
      Patients will be included in this study are patients with diabetes mellitus and secondary
      failure to monotherapy. Will also assess the effect of combined therapy on the oral lipid
      profile (total cholesterol, LDL, HDL, VLDL, Triglycerides) and on the sensitivity and insulin
      secretion. We evaluate the clinical measurements, laboratory and safety during 3 months,
      through the allocation of subjects to three study groups (metformin, glimepiride and
      metformin extended release / glimepiride)
    
  